Wikipedia -WSS

Wikipedia

author：hotspot 2025-10-02 00:43:04 - browse：4918

A woman walks in San Francisco, with her father who has Alzheimer's – public health and science coverage from STAT — Ben Margot/AP

A host of hurdles are slowing the adoption of the new Alzheimer’s drug Leqembi, experts involved in the treatment of patients said Wednesday, from complicated logistics to the fact that many people don’t recognize that their memory loss is a disease soon enough.

Some patients still grapple with whether they want to be diagnosed, even though a treatment exists, the experts said, speaking during a STAT virtual event.

“Even the word for dementia does not always exist in every culture and in every language,” said Hollis Day, chief of geriatrics at Boston Medical Center and a professor at Boston University’s medical school. “And so just getting people to accept that memory loss is not normal aging necessarily, is a big barrier to getting people into diagnosis early enough to benefit from these treatments.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Eli Lilly’s Zepbound improved liver scarring in mid

explore

WSS

CMS got Medicare Advantage quality rating wrong, judge rules

Option Care buys Amedisys in $3.6 billion home care deal

Option Care buys Amedisys in $3.6 billion home care deal

CMS got Medicare Advantage quality rating wrong, judge rules

Why is France rioting? What to know about the fatal police shooting of Nahel M

ASCO Daily Recap: CAR

knowledge

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

As demand for Covid shots wanes, Moderna seeks its next success

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Medicare details structure of new drug price negotiation program

Congress needs to close a vaccine

At least 13 dead in Texas as scorching temps continue

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Virginia high school admissions case could be legal follow

Congress needs to close a vaccine

How one medical school became remarkably diverse

Inside the fall of star MIT scientist David Sabatini

focus

STAT wants to know your pick for a great summer read or listen

Data don't support strong claims for Covid

Stopping antidepressants leads to symptoms for 1 in 6 patients

These geoengineering technologies could help combat the climate crisis, scientists say

Bacterial infection may be ‘key event’ in endometriosis, study says

Listen: Biogen's messy board & Laronde's data problem

explore

explore

hotspot

focus